Carl Gustaf Nilsson, M.D. t:j: Hannu Allonen, M.D. Juan Diaz, M.D.II Tapani Luukkainen, M.D., Ph.D.t
|
|
- Jeremy Carson
- 5 years ago
- Views:
Transcription
1 FERTILITY AND STERILITY Copyright The American Fertility Society Vol. 39, No.2, February 1983 Printed in U.8A. Two years' experience with two levonorgestrel-releasing intrauterine devices and one copper-releasing intrauterine device: a randomized comparative performance study* Carl Gustaf Nilsson, M.D. t:j: Hannu Allonen, M.D. Juan Diaz, M.D.II Tapani Luukkainen, M.D., Ph.D.t University of Helsinki, Helsinki, Finland, University of Turku, Turku, Finland, and Centro de Pesquisas e Cantrale das Doencas Materna-Infantis de Campinas-CEMICAMP, Sao Paulo, Brazil A randomized comparative performance study of two levonorgestrel intrauterine devices (IUDs) and a copper (Nova-T) IUD (Leiras, Turku, Finland) was performed at two clinics in Finland and one in Brazil. The 24-month cumulative event rates per 100 women are reported. Six thousand woman-months of use were recorded with the levonorgestrel IUD and 3000 with the Nova-T device. Pregnancy rates at 2 years of use were 0.6 and 0 with the two levonorgestrel IUDs and 3.3 with the Nova-T IUD. Removal rates because of bleeding and/or pain were low with all three IUDs: 7.5, 7.6, and 7.1, respectively, at 24 months. Recordings of the number of days of bleeding showed significantly fewer days of bleeding during use of the levonorgestrel IUDs than the Nova-T IUD from the second month of use onward, until the end of the second year. No infections were recorded in association with use of the levonorgestrel IUDs, and only one termination because of infection was recorded for the Nova-T IUD. The continuation rates of use at 24 months were 66.6, 60.7, and 71.9 for the two levonorgestrel IUDs and the Nova-T IUD, respectively; the differences were not statistically significant. Fertil Steril 39:187, 1983 Received May 20, 1982; revised and accepted October 7, *This work was undertaken as part of the contraceptive development programs sponsored and coordinated by the International Committee for Contraception Research and the Population Council, New York, New York. Financial support was provided by the International Development Research Center of Canada, the Ford Foundation, and the Rockefeller Foundation, New York, New York. tsteroid Research Laboratory, Department of Medical Chemistry, University of Helsinki. treprint requests: Dr. Carl Gustaf Nilsson, Steroid Research Laboratory, Department of Medical Chemistry, University of Helsinki, Siltavuorenpenger 10 A, SF Helsinki 17, Finland. Department of Pharmacology, Institute of Biomedicine, University of Turku. IICentro de Pesquisas e Controle das Doencas Materno-Infantis de Campinas-CEMICAMP. When the development of a new contraceptive method has reached the state of clinical trials, a comparison with an established, well-performing method becomes necessary. The so-called clinic effect is a recognized feature in studies of intrauterine contraceptive devices (IUDs).l To avoid the bias imposed by this phenomenon, IUD studies should be comparative and randomized. The choice of the object of comparison in IUD studies has often been the CuT -200 device (Leiras, Turku, Finland). The development of the new levonorgestrel-releasing IUD is now in the phase of clinical trials. The first results of these studies have been published. 2, 3 The trials have been conducted as randomized comparative performance studies, using the Nova-T copper-releasing IUD Vol. 39, No.2, February,1983 Nilsson et ai. Levonorgestrel IUD: 2 years' experience 187
2 % Levonorgestrel A D Levonorgestrel B Nova -T < >35 Age Figure 1 Age distribution of the patients. (Leiras) for comparison. The choice of the Nova-T for this comparison was made because the levonorgestrel-releasing IUD utilizes the plain Nova T design as the carrier for levonorgestrel and because the Nova-T has shown better clinical performance in multicenter randomized trials in comparison with the CuT-200.4, 5 This report covers the first-segment 2-year cumulative net rates per 100 women using two levonorgestrel-releasing IUDs and the Nova-T device. MATERIALS AND METHODS The IUDs were inserted at three different outpatient clinics, two in Finland and one in Brazil. Similar insertion instructions and criteria for patient enrollment were used at all three clinics. Special admission and follow-up forms and cards for registering bleeding were designed for the study. The three IUDs were assigned at random, and the women were not told which of the three IUDs was inserted. The admission form was sealed after insertion, and the study was thereafter carried out double-blind. After the 1-year follow-up visit, the women were told on request which IUD had been inserted. The device was inserted between the third and seventh day of the cycle. No additional contraception was used after the insertion. Follow-up visits were scheduled at 3, 6, 12, and 24 months after insertion. Three different IUDs were used, two levonorgestrel-releasing IUDs and one copper-releasing Nova-T device. The properties of all three IUDs have been described in detail. 6,7 The levonorgestrel IUDs were called A and B, and the difference between them was only in the amount of 188 Nilsson et al. Levonorgestrel IUD: 2 years' experience levonorgestrel released daily in utero. Device A was designed to release 20 ILg, and device B, 30 ILg of levonorgestrel daily. The insertion technique was identical for all three devices. Voluntary patients were enrolled for the study by the following criteria: accessibility for regular follow-up; a history of at least one pregnancy, age between 18 and 38 years; not pregnant or breastfeeding at the start of the study; no former use of a long-acting hormonal preparation; and no hormonal treatment in the previous 6 months. Patients with a history of ectopic pregnancy were excluded, but no other exclusions were made on the grounds of medical history if at the time of enrollment the patient was regarded as being healthy. Informed consent was obtained from every patient. The following IUDs were inserted: 164 A-Ievonorgestrel IUDs, 163 B-Ievonorgestrel IUDs, and 157 Nova-T IUDs. Every visit was recorded, and the data were sent to a central office. When more than 2 years had elapsed from the time of insertion, the results were analyzed by the life-table method of Potter8 with the use of a digital computer program. Group means of the number of days of bleeding were tested for two-sided significance by the t-test (IUD A versus the Nova-T, and IUD B versus the Nova-T). RESULTS Figures 1 and 2 show the age and parity distribution of the women. No significant differences % Levonorgestrel A D Levonorgestrel B Nova -T o II ~III Parity Figure 2 Parity distribution of patients in a randomized comparative performance study of two levonorgestrel IUDs and a Nova-T IUD. Fertility and Sterility
3 - Table 1. A Randomized Comparative Performance Study of Two Levonorgestrel IUDs and a Nova-T Copper IUD: The 24-Month Cumulative Event Rates per 100 Women Levonorgestrel Levonor- gestrel Nova-T A B Rates Accidental preg nancy Expulsiona Removal Medical Bleeding and/or painb Amenorrhea Hormonal c Infection Other Personal Planning preg nancy Other Continuation No. of first inser tions Woman-months of use apartial and complete expulsions. bheavy bleeding, intermenstrual spotting, pain, bleeding and pain. <Weight gain, acne, hirsutism, mental change. were recorded between the IUD groups. Table 1 shows the results of the life-table analysis at 24 months. The net cumulative pregnancy rates were 0.6 (A) and 0.0 (B) for the two levonorgestrel IUDs and 3.3 for the Nova-T at 24 months of use. The corresponding gross rates were 0.6 (A), 0.0 (B), and 3.7 (Nova-T). The Pearl indices at 24 months of use were 0.4 (A) and 0.0 (B) for the levonorgestrel IUDs and 2.0 for the Nova-T. The differences in pregnancy rates for the IUDs were not statistically significant. The net rates of removal because of bleeding and/or pain (including heavy bleeding, intermenstrual spotting, pain, and bleeding and pain) were below 8 for all three IUDs: 7.5 for A, 7.6 for B, and 7.1 for the Nova-T after 2 years of use. The differences were not significant. Figure 3 shows the monthly cumulative net rates of removal because of bleeding and/or pain. The monthly removal rate was lower for the Nova-T during the course of the study, but by 24 months all three IUDs were associated with the same net rate of removal. Figure 4 shows the monthly cumulative net rates of expulsion. Only one A levonorgestrel IUD was expelled during the 24 months of use. Five B Vol. 39, No.2, February 1983 levonorgestrel IUDs were expelled, all during the first 5 months of use, while a total of nine Nova Ts were expelled, the last of which was recorded at the 24-month follow-up visit. The net rates of expulsion were 0.6, 3.1, and 6.1 for the A and B levonorgestrel IUDs and the Nova-T, respectively. The differences were not significant. The 24-month net cumulative rates of removal because of amenorrhea were 10.7 for the A levonorgestrel IUD and 12.4 for the B levonorgestrel IUD, while there were no removals because of amenorrhea in the Nova-T group. The removal rates because of amenorrhea for the A levonorgestrel IUD (P < 0.01) and the B levonorgestrel IUD (P < 0.001) were significantly greater than that of the Nova-T device. Figure 5 shows the monthly net cumulative removal rates because of amenorrhea for both levonorgestrel IUDs. The removal rate was higher for the B levonorgestrel IUD, releasing greater amounts oflevonorgestrel, than it was for the A levonorgestrel IUD during all 24 months of use. There was a sharp rise in the removal rates for both IUDs at the 13th month of use, which time coincided with that of the I-year follow-up visit. Hormonal reasons for removal were weight gain, acne, hirsutism, or mental changes. There were no significant differences between the IUDs in the net rates of removal because of hormonal reasons. The rates were 6.7 and 4.1 for the A and B levonorgestrel IUDs, respectively, and 1.3 for the Nova-T. The highest removal rate for hormonal reasons was thus recorded for the levonorgestrel IUD with the lower release rate of levonorgestrel, and removals of the nonhormonal Nova-T device were also performed. There were no removals of either levonorgestrel IUD because of infection, and only one Nova T was removed for this reason (rate, 0.8). 20! ~ 10 Iii z! ~ o A-- B c MOnths Figure 3 Monthly cumulative net rates of removal because of bleeding and/or pain of two levonorgestrel IUDs (A and B) and a Nova T IUD (C). Nilsson et ai. Levonorgestrel IUD: 2 years' experience 189
4 A-- B C.-.-._._._ Ordinal month Figure 4 Monthly cumulative net rates of expulsion of two levonorgestrel IUDs (A and B) and a Nova-T (e). Removals because of other medical and other personal reasons were of the same order for all three IUDs. The continuation rates after 24 months of use were 66.6, 60.7, and 71.9 for the A and B levonorgestrel IUDs and the Nova-T, respectively. The differences in continuation rates between the three IUDs were not statistically significant. The numeric difference in continuation rate between the two levonorgestrel IUDs was due to the relatively great difference in removals because of planning pregnancy: 2.1 and 7.7 for the A and B levonorgestrel IUDs, respectively. The differences in continuation rates between the Nova-T and the two levonorgestrel IUDs were the result of the high removal rates due to amenorrhea associated with the levonorgestrel IUDs. Figure 6 shows the average number of days of bleeding during each of the first 24 months of use of the three IUDs. The days of bleeding were calculated from the records kept by every patient, and the average number of days of bleeding during the first postinsertion month was the same for all three devices. Already during the second month of use the number of days of bleeding was significantly lower with the A levonorgestrel IUD (P < 0.001) and the B levonorgestrel IUD (P < 0.02) than with the Nova-T. This difference lasted to the end of the second year of use. Table 2 shows the annual gross rates of events per 100 women. The pregnancy rate was 0 during both the first and second year of use of the B levonorgestrel IUD and 0.6 and 0, respectively, for the A levonorgestrel IUD. The corresponding figures for the Nova-T were 2.7 during the first year and 1.0 during the second year of use. No expulsions were recorded during the second year 190 Nilsson et al. LevonorgestrellUD: 2 years' experience of use of both levonorgestrel IUDs, and the rate of Nova-T expulsions decreased from 4.6 during the first year to 0.2 during the second year. Removal rates because of bleeding and/or pain were 5.6 and 5.8 for the A and B levonorgestrel IUDs, respectively, during the first year of use, and the rates decreased to 2.5 and 3.0 during the second year, while the rate increased from 2.6 during the first year to 5.4 during the second year with the use of the Nova-T. DISCUSSION Despite the improvements achieved in IUD performance with the new copper-medicated IUDs, bleeding and/or pain still remains the most common single cause for removal of an IUD. Improvements in patterns of bleeding have certainly occurred in association with the use of the copperreleasing IUDs, compared with the nonmedicated plastic IUDs. The life-table method of analysis of IUD performance, however, is not capable of discriminating between subgroups of reasons for removals because of disturbances of bleeding. In particular, the effect of alterations in the amount of blood loss during IUD use is not reflected by the figures reporting removals because of bleeding and/or pain by the life-table method. Rather, this method reflects irregular bleeding and bleeding episodes of abnormal length. The results of the present study show very low net cumulative removal rates because of bleeding and/or pain at 24 months of use. The rates for all three IUDs were below 8, which is markedly lower than corresponding figures reported in recent comparative studies. 4, 9, 10 The CuT-380A, CuT-200, and Nova-T have been associated with a net cumulative removal rate on the order of 15 to 20 because 20.! ~ 10 w z ~ i ~ o " A-- B ,.-_... f--'" Figure 5 Monthly cumulative net rates of removal because of amenorrhea of two levonorgestrel IUDs (A and B). B r Months Fertility and Sterility
5 ~ \ \ til C :s CD ~ d-ng-iud A d-ng-iud B Nova-T Figure 6 Average number of days of bleeding during each of the first 24 months of use of two levonorgestrel IUDs (A and B) and a Nova-T IUD., 15 months of bleeding and/or pain at 24 months of use.4, 11 The number of days of bleeding was highly significantly lower throughout the 2-year period in association with use of the levonorgestrel IUDs than with the Nova-T in the present study. However, the figures for removal because of bleeding and/or pain were equal for all three devices. Although these circumstances did not result in more favorable continuation rates for the levonorgestrel IUDs than for the Nova-T, they are healthpromoting by virtue of the decreased blood loss and by the higher hemoglobin concentrations in the peripheral blood of women using the levonorgestrel IUDs.12 In a population with poor nutritional conditions and a high frequency of anemia, this difference in the effect on the amount of menstrual blood loss associated with the use of levonorgestrel IUDs and copper-releasing IUDs becomes still more important. Locally administered levonorgestrel has a profound effect upon the endometrium, which becomes atrophic and inactive, with scarce glands and no mitotic activity.13 Because of this local effect, amenorrhea develops in a certain percentage of levonorgestrel IUD users. Ovulation, however, is not suppressed.14 Menstrual bleeding is restored within 1 month after removal of the levonorgestrel IUD,15 and recovery of fertility has been shown not to be affected by the use of a levonorgestrel IUD.16 Removals because of amenorrhea were performed at net rates of 10.7 (A levonorgestrel IUD) and 12.4 (B levonorgestrel IUD) after 24 months of use in the present study. The monthly cumulative net rate curve (Fig. 5) shows that most of the removals because of amenorrhea were performed at the time of the I-year follow-up visit, i.e., at the 13th month of use. The women, having been informed of the possibility of amenorrhea during use of the IUDs before entering the study, in very few cases personally requested removal because of amenorrhea. The removals were mainly performed as a result of the doctor's decision, and this in turn was due to the fact that no special policy was agreed upon with regard to the management of amenorrhea cases among the physicians participating in the study. If the rates of removal because of amenorrhea in the levonorgestrel IUD groups are omitted from the calculations as not being a negative side effect of IUD use, the net cumulative continuation rates at 2 years of IUD use rise to 77.3 and 73.1 for the A and B levonorgestrel IUDs, respectively, which is a very high continuation rate for any method of reversible contraception. The removal rates for hormonal reasons were equal for all three devices during the first year of use, when the women did not know which IUD they were using. The Nova-T was also removed for hormonal reasons. During the second year of use, the removal rates for hormonal reasons were Table 2. Annual Gross Rates of Events per 100 Women IUD A First year IUDB Pregnancy Expulsion Removal Bleeding and/or pain Amenorrhea Hormonal Other medical reasons Second year Nova-T IUD A IUDB Nova-T Vol. 39, No.2, February 1983 Nilsson et al. Levonorgestrel IUD: 2 years' experience 191
6 higher in association with the levonorgestrel IUDs than with the Nova-T, the women then knowing which IUD they were using. No infections were recorded during the 24- month use of either levonorgestrel IUD, and the infection rate was also very low with the use of the Nova-T. A total experience of over 20,000 woman-months of use of the levonorgestrel-releasing IUDs has been accumulated. Only three cases of pelvic inflammatory disease have been recorded thus far. 17 The overall experience and the data of the present study suggest that the use of a levonorgestrel-releasing IUD is not associated with an increased risk of pelvic infection and that there is a probability that a levonorgestrel IUD may in fact provide protection similar to that of oral contraceptives against infection,18 through its local hormonal mode of action. The levonorgestrel-releasing IUDs of the present study have an estimated lifetime of 7 years. The overall removal rates because of bleeding and/or pain during the first 2 years of use were extremely low; and, moreover, there was a decline in the rates of removal because of bleeding and/or pain during the 2nd year of use. Only one pregnancy occurred in association with the use of the A levonorgestrel IUD during the 1st year of use and none during the 2nd year, while no pregnancies occurred during the 2-year follow-up period in association with use of the B levonorgestrel IUD. The Pearl indices after 2 years of use were as low as 0.39 (A) and 0.00 (B) for the two levonorgestrel IUDs. Acknowledgment. This study would not have been possible without the valuable cooperation of the personnel of the participating countries. REFERENCES 1. Mishell DR Jr: The clinic factor in evaluating IUDs. In Analysis of Intrauterine Contraception, Edited by F Hefnawi, SJ Segal. Proceedings of the Third International Conference on Intrauterine Contraception, Cairo, Amsterdam, Elsevier-North Holland Publishing Co., 1975, p Nilsson CG, Luukkainen T, Diaz J, Allonen H: Intrauterine contraception with levonorgestrel: a comparative randomized clinical performance study. Lancet 1:557, Luukkainen T, Nilsson CG, Toivonen J: New methods for the regulation of female fertility. Proceedings ofthe Third World Congress of Human Reproduction, West Berlin, Amsterdam, Excerpta Medica, AHonen H, Luukkainen T, Nielsen N-C, Nygren K-G, Pyorala T: Two-year rates for Nova T and Copper T in a comparative study. Contraception 21:321, Nygren K-G, Nielsen N-C, Pyorala T, Allonen H, Luukkainen T: Intrauterine contraception with Nova-T and Copper-T 200 during three years. Contraception 24:529, Nilsson CG, Lahteenmaki P, Robertson DN, Luukkainen T: Plasma concentrations of levonorgestrel as a function of the release rate of levonorgestrel from medicated intrauterine devices. Acta Endocrinol (Copenh) 93:380, Luukkainen T, Nielsen N-C, Nygren K-G, Pyorala T, Kosonen A: Randomized comparison of clinical performance of two copper-releasing IUDs, Nova-T and copper-t-200. Contraception 19:1, Potter RG Jr: Application of life-table techniques to measurement of contraceptive effectiveness. Demography 3:297, Jain AK: Safety and effectiveness of intrauterine devices. Contraception 11:243, Tatum HJ: Comparative experience with newer models for the Copper T in the United States. In Analysis of Intrauterine Contraception, Edited by F Hefnawi, SJ Segal. Proceedings of the Third International Conference on Intrauterine Contraception, Cairo, Amsterdam, Elsevier-North Holland Publishing Co., 1975, p Sivin I, Tatum HJ: Four years of experience with the TCu 380A intrauterine contraceptive device. Fertil Steril 36:159, Nilsson CG: Comparative quantitation of menstrual blood loss with a d-norgestrel-releasing IUD and a Nova-T copper device. Contraception 15:379, Nilsson CG, Luukkainen T, Arko H: Endometrial morphology in women using a d-norgestrel-releasing intrauterine device. Fertil Steril 29:397, Nilsson CG, Lahteenmaki P, Luukkainen T: Levonorgestrel plasma concentrations and hormone profiles after insertion and after one year oftreatment with a levonorgestrel-iud. Contraception 21:225, Nilsson CG: A d-norgestrel-releasing IUD. Thesis, University of Helsinki, Nilsson CG: Fertility after discontinuation of levonorgestrel-releasing intrauterine devices. Contraception 25:273, Nilsson CG: Unpublished data 18. Ryden G, Fahraens L, Molin L, Ahman K: Do contraceptives influence the incidence of acute pelvic inflammatory disease in women with gonorrhea? Contraception 20:149, Nilsson et al. Levonorgestrel IUD: 2 years' experience Fertility and Sterility
Product Information. Confidence that lasts
Confidence that lasts What is Mirena? Inhibition of sperm motility and function inside the uterus and the fallopian tubes, preventing fertilization (Videla-Rivero et al. 1987). Section of system Levonorgestrel
More informationReview of IUCD Complications: Lessons from CAT. Dr FG Mhlanga CAT Meeting 24 September 2016
Review of IUCD Complications: Lessons from CAT Dr FG Mhlanga CAT Meeting 24 September 2016 INTRODUCTION The intrauterine device (IUD) is a reliable long term reversible, cost-effective,easy to use and
More informationREPRODUCTIVE ENDOCRINOLOGY
FERTILITY AND STERILITY VOL. 79, NO. 4, APRIL 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY
More informationA contraceptive subdermal implant releasing the progestin S1-1435: ovarian function, bleeding patterns, and side effects*t
FERTILITY AND STERILITY Vol. 58, No.6, December 1992 Copyright CI 1992 The American Fertility Society Printed on ocid-free paper in U.S.A. A contraceptive subdermal implant releasing the progestin S1-1435:
More informationApplication for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines
Application for inclusion of levonorgestrel - releasing IUD for contraception in the WHO Model List of Essential Medicines 1. Summary statement of the proposal for inclusion LNG-IUS is an effective contraceptive;
More informationInternational Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:
Review Article ISSN: 2319 9563 International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage: www.ijrpns.com A REVIEW ON INTRAUTERINE DEVICES Boddu Venkata Komali* 1, M. Kalyani
More information1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S.
1 2 1. Ortiz, M. E et al. Mechanisms of action of intrauterine devices. Obstet & Gynl Survey 1996; 51(12), 42S-51S. The contraceptive action of all IUDs is mainly in the uterine cavity. The major effect
More informationReproductive health research at WHO
Reproductive health research at WHO Paul F.A. Van Look, MD PhD Department of Reproductive Health and Research World Health Organization Geneva, 11 March 2004 PVL_GE_StudCourse_MAR04/1 Health is a state
More informationUnintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use
3:45 4:30 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationLEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common
4:15 5 pm Beyond the Pill: Long Acting Contraceptives and IUDs Presenter Disclosure Information The following relationships exist related to this presentation: Christine L. Curry, MD, PhD: No financial
More informationDownloaded from:
French, R; Cowan, F; Mansour, D; Morris, S; Hughes, D; Robinson, A; Proctor, T; Summerbell, C; Logan, S; Guillebaud, J (2001) Hormonally impregnated intrauterine systems (IUSs), versus other forms of reversible
More informationWelcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.
Mirena is the #1 prescribed IUD * in the U.S. Welcome to Mirena The Mirena Handbook: A Personal Guide to Your New Mirena *Intrauterine Device Supported by 2015-2016 SHS data INDICATIONS FOR MIRENA Mirena
More informationWhat s New in Adolescent Contraception?
What s New in Adolescent Contraception? Abby Furukawa, MD Legacy Medical Group Portland Obstetrics and Gynecology April 29, 2017 Objectives Provide an update on contraception options for the adolescent
More informationA PROSPECTIVE RANDOMIZED STUDY OF THE COPPER 7, MULTILOAD Cu 250 AND COPPER 220C IUDS IN SINGAPORE
A PROSPECTIVE RANDOMIZED STUDY OF THE COPPER 7, MULTILOAD Cu 250 AND COPPER 220C IUDS IN SINGAPORE TG McCarthy LSLim S M M Karim S S Ratnam Department of Obstetrics and Gynaecology National University
More informationA systematic review of some of the side effects of copper T380 intrauterine contraceptive device
A systematic review of some of the side effects of copper T380 intrauterine contraceptive device Ahmed Nehad Ahmed Hatem Askalani IAMANEH Scholarship Reproductive Health Research Course Geneva, 2006 Introduction
More informationthe IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to
your guide to Helping you choose the method of contraception that s best for you IUD IUD the e IUD IU IUD the IUD 2 3 The intrauterine device (IUD) An IUD is a small plastic and copper device that s put
More informationInstruction for the patient
WS 4 Case 3 STI and IUD Your situation Instruction for the patient You are 32 years old, divorced and have one child; you have just started a new relationship You underwent surgical resection of the left
More informationA Comparative Study between the Side Effects of Copper Intrauterine Device in Women with Non-scarred and Scarred Uterus
Iraqi JMS Published by Al-Nahrain College of Medicine ISSN 161-659 Email: Iraqi_jms_alnahrain@yahoo.com http://www. colmed-nahrain.edu.iq/ A Comparative Study between the Side Effects of Copper Intrauterine
More informationNon-contraceptive Uses of the Levonorgestrel Intrauterine Device Elena Gates, MD http://www.mirena-us.com/pvs1/pri/whatisframe.html Progestin levels with LNG- IUS Lower plasma levels Mirena 150-200 pg/ml
More informationREPRODUCTIVE ENDOCRINOLOGY
REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 76, NO. 2, AUGUST 2001 Copyright 2001 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in
More informationSimplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok
Simplifying Vide Contraception University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok Background Objectives At the conclusion of this presentation participants will be able
More informationGynaecology Forum. Regine Sitruk-Ware. The levonorgestrelreleasing intrauterine. system, Mirena. Vol. 11, No. 2, Guest Editor: In this issue:
Gynaecology Forum Vol. 11, No. 2, 2006 Guest Editor: Regine Sitruk-Ware In this issue: The levonorgestrelreleasing intrauterine system, Mirena Contraceptive efficacy and safety Use in nulliparous women
More informationFamily Planning UNMET NEED. The Nurse Mildred Radio Talk Shows
Family Planning UNMET NEED The Nurse Mildred Radio Talk Shows TOPIC 9: IUD/COIL Guests FP counsellor from MSU, RHU& UHMG Nurse Mildred Nurse Betty Objectives of the programme: To inform listeners about
More informationTHE INTRA--UTERINE DEVICE
CANADIAN CONSENSUS CONFERENCE THE INTRA--UTERINE DEVICE WHY CONSIDER THIS METHOD? Use of an IUD should be considered for all women who seek a reversible, effective, coitally-independent method of contraception.
More informationEmergency Contraception THE FACTS
Emergency Contraception Quick Facts What is it? Emergency contraception is birth control that you use after you have had unprotected sex--if you didn t use birth control or your regular birth control failed.
More informationLevosert levonorgestrel 20mcg/24hour intrauterine device
Levosert levonorgestrel 20mcg/24hour intrauterine device Verdict: Formulary inclusion: Formulary category: Restrictions: Reason for inclusion: Link to formulary: Link to medicine review summary: Levosert
More information1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:
1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a
More information1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7:
1 2 1. Attia AM et al. Role of the levonorgestrel intrauterine system in effective contraception. Patient Prefer Adherence 2013; 7: 777 85. 3 1. Wu JP et al. Extended use of the intrauterine device: a
More informationClinica Ostetrica e Ginecologica I, Istituto Luigi Mangiagalli, University of Milano, Milan, Italy
FERTILITY AND STERILITY VOL. 80, NO. 2, AUGUST 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Inc. Printed on acid-free paper in U.S.A. Comparison of a levonorgestrel-releasing
More informationThe Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.
The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings Counseling Cards Checklist to be reasonably sure a woman is not pregnant
More informationTreatment of menorrhagia with a novel frameless intrauterine levonorgestrelreleasing drug delivery system: a pilot study
European Journal of Contraception & Reproductive Health Care, 2001;6:93-101 Treatment of menorrhagia with a novel frameless intrauterine levonorgestrelreleasing drug delivery system: a pilot study D. Wildemeersch*,
More informationSexual and reproductive health research at WHO
Sexual and reproductive health research at WHO Paul F.A. Van Look, MD PhD Department of Reproductive Health and Research World Health Organization Geneva, 4 March 2005 05_GE_StudCourse_MAR/1 Health is
More informationArdhanu Kusumanto Oktober Contraception methods for gyne cancer survivors
Ardhanu Kusumanto Oktober 2017 Contraception methods for gyne cancer survivors Background cancer treatment Care of gyn cancer survivor Promotion of sexual, cardiovascular, bone, and brain health management
More informationSummary of analysis of efficacy and safety of Implantable Contraceptives (levonorgestrel and etonogestrel releasing implants).
Expert Committee Member comment on application for Implantable contraceptives (levonorgestrel and etonogestrel releasing implants) to be added to the WHO Model List Summary of analysis of efficacy and
More informationInformation for Informed Consent for Insertion of a Mirena IUD
Information for Informed Consent for Insertion of a Mirena IUD What is an IUD (intrauterine Device)? An intrauterine device (IUD) is a plastic device that is placed into your uterus to prevent pregnancy.
More informationThe Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH
The Doctor Is In Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH Contraception Resources from the CDC: 2016 U.S. Medical Eligibility Criteria
More informationIdentification of main risk factors for tubal infertility*
FERTILITY AND STERILITY Copyright 1994 The American Fertility Society Printed on acid-free paper in U. S. A. Identification of main risk factors for tubal infertility* Luis Bahamondes, M.D., Ph.D.t:j:
More informationIUD USE EFFECTZVENESS IN AN URBAN GUATEMALAN CLINIC
IUD USE EFFECTZVENESS IN AN URBAN GUATEMALAN CLINIC Penny Prior,2 Paul N. Seward,,3 Federico Staackman,4 Luis F, Galich, 5 Cynthia Burski,6 and Leo Morris7 Contraceptive continuation ratesthe rates at
More information2
1 2 3 1. Usinger KM et al. Intrauterine contraception continuation in adolescents and young women: a systematic review. J Pediatr Adolesc Gynecol 2016; 29: 659 67. 2. Kost K et al. Estimates of contraceptive
More informationExtended use of the intrauterine device: a literature review and recommendations for clinical practice,
Contraception 89 (2014) 495 503 Review Extended use of the intrauterine device: a literature review and recommendations for clinical practice, Justine P. Wu, Sarah Pickle Department of Family Medicine
More informationCOLLECTION OF CRITICALLY APPRAISED TOPICS ON CONTRACEPTION
COLLECTION OF CRITICALLY APPRAISED TOPICS ON CONTRACEPTION Progestin only pills The Evidence Based Medicine Center, Department of Obstetrics, Gynecology and Reproductology, Ukraine National Medical Academy
More informationlevonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer
levonorgestrel 13.5mg intrauterine delivery system (Jaydess ) SMC No. (1036/15) Bayer 6 March 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises
More informationLONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables
LONG-ACTING REVERSIBLE CONTRACEPTION Summary Tables Bridging the Divide: A Project of the Jacobs Institute of Women s Health June 2016 Table 1. Summary of LARC Methods Available Years Since Effective Copper
More informationManagement of Emergency Contraception (EC)
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Management of Emergency Contraception (EC) The risks and benefits of an IUD or oral EC should be discussed and documented (see appendix). Reasonable measures
More informationCLINICAL INVESTIGATION OF ORAL CONTRACEPTIVES
CLINICAL INVESTIGATION OF ORAL CONTRACEPTIVES Guideline Title Clinical Investigation of Oral Contraceptives Legislative basis Directive 75/318/EEC as amended Date of first adoption February 1987 Date of
More informationFitting of an Intrauterine Device (IUD)
PLEASE PRINT WHOLE FORM DOUBLE SIDED ON YELLOW PAPER Patient Information to be retained by patient affix patient label What is an IUD? An IUD is a small T-shaped plastic and copper device that is put into
More informationFDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)
FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system) Mirena does not protect against HIV infection (AIDS) and other sexually transmitted infections
More informationRisk factors for IUD failure: results of a large multicentre case control study
Human Reproduction Vol.21, No.10 pp. 2612 2616, 2006 Advance Access publication June 14, 2006. doi:10.1093/humrep/del208 Risk factors for IUD failure: results of a large multicentre case control study
More informationOpen randomised study of use of levonorgestrel releasing intrauterine system as alternative to hysterectomy
The Interagency Group on Breastfeeding Monitoring is a coalition of organisations and individuals established to monitor independently the marketing code. Dr Anthony Williams and Professor Andrew Tomkins
More informationBreast Cancer Risk in Patients Using Hormonal Contraception
Breast Cancer Risk in Patients Using Hormonal Contraception Bradley L. Smith, Pharm.D. Smith.bradley1@mayo.edu Pharmacy Ground Rounds Mayo Clinic Rochester April 3 rd, 2018 2017 MFMER slide-1 Presentation
More informationContraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014
Contraception Tami Allen, RNC OB, MHA Robin Petersen, RN, MSN Perinatal Clinical Nurse Specialist Objectives Discuss the impact of unintended pregnancy in the United States Discuss the risks and benefits
More informationFamily Planning د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد
Family Planning د. نجمه محمود كلية الطب جامعة بغداد فرع النسائية والتوليد Objectives:- To know the different types of contraception To know the failure rate & mechansim of action of each type To explain
More informationIntrauterine delivery of progestogen in the peri- and postmenopausal women. Outline of the presentation. Levonorgestrel releasing IUS - Mirena
QuickTime ja Valokuva - JPEG pakkauksen purkuohjelma tarvitaan elokuvan katselemiseen. Intrauterine delivery of progestogen in the peri- and postmenopausal women ESHRE Campus meeting 6.-7.10.2008 Oskari
More informationContraceptives. Kim Dawson October 2010
Contraceptives Kim Dawson October 2010 Objectives: You will learn about: The about the different methods of birth control. How to use each method of birth control. Emergency contraception What are they?
More informationTable I. Examples of Hormone and Tapering Regimens
Table I. Examples of Hormone and Tapering Regimens Severe AUB Heavy bleeding (soaking through 2 maxi pads an hour, 2 hours in a row) History of heavy menses Hemodynamically un (tachycardia, hypotensive,
More informationProgramme s priorities for development of new fertility regulation technologies. World Bank Special Programme
World Bank Special Programme of Research, Development and Research Training in Human Reproduction: Programme s priorities for development of new fertility regulation technologies. Progress in human reproductive
More informationFertility control: what do women want?
FIAPAC 2018 Fertility control: what do women want? Dr. Raymond H.W. Li MBBS, MMedSC, FRCOG, FHKAM (O&G) Cert RCOG/HKCOG (Reprod Med) Department of O&G, The University of Hong Kong The Family Planning Association
More informationBLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018
BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018 Introduction Bleeding with contraception may lead to discontinuation and possible unintended pregnancy What
More informationIntrauterine and subdermal progestin administration postmenopausal hormone replacement therapy
FERTILITY AND STERILITY Vol. 63, No.2, February 1995 Copyright c 1995 American Society for Reproductive Medicine Printed on acid-free paper in U. S. A. Intrauterine and subdermal progestin administration
More informationEndometrial Cancer Biopsy of the endometrium Evaluation of women of all ages
Endometrial Cancer Biopsy of the endometrium Evaluation of women of all ages Barbara S. Apgar, MD, MS Professor of Family Medicine University of Michigan Health System Ann Arbor, Michigan Cancer of the
More informationFACT SHEET: Copper IUD
FACT SHEET: Copper IUD How does the copper IUD help me? The copper IUD is a hormone-free option. If you don t like the copper IUD or you decide to get pregnant, your health care provider can remove the
More informationLARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures
LARC: Long Acting Reversible Contraception Disclosures I have no relevant financial disclosures Jennifer Kerns, MD, MPH Assistant Professor, UCSF Obstetrics, Gynecology and Reproductive Sciences San Francisco
More informationContraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE
Contraception Choices: An Evidence Based Approach Case Study Approach Susan Hellier PhD, DNP, FNP-BC, CNE Objectives Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC)
More informationBirth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy
Birth Control- an Overview Keith Merritt, MD Basics Remember, all methods of birth control are safer and have fewer side effects than pregnancy Even with perfect use, each method of birth control has a
More informationOrals,Transdermals, and Other Estrogens in the Perimenopause
Orals,Transdermals, and Other Estrogens in the Perimenopause Cases Denise Black, MD, FRCSC Assistant Professor, Obstetrics, Gynecology and Reproductive Sciences University of Manitoba 6/4/18 197 Faculty/Presenter
More informationContraception. IUC s, Sterilization
Contraception IUC s, Sterilization Intrauterine Contraceptives (IUC s) IUC s are made of flexible plas4c, available only through prescrip4on Three types ParaGard (copper) Mirena (hormone) Skyla (hormone)
More informationالحمد هلل رب العالمين والصالة والسالم علي محمد الصادق الوعد األمين اللهم أخرجنا من ظلمات الجهل والوهم إلى نور المعرفة والعلم..
الحمد هلل رب العالمين والصالة والسالم علي محمد الصادق الوعد األمين اللهم أخرجنا من ظلمات الجهل والوهم إلى نور المعرفة والعلم.. سيدنا 11/6/2013 1 Goals of Family Planning services : 1- Enable women and
More informationDr. Russo reports no financial relationships relevant to this article. Dr Creinin is a senior clinical advisor for Medicines360.
CONTRACEPTION Demand for long-acting reversible contraception is growing, including in adolescents and nulliparas. We need to challenge our historical reservations about the IUD and heed the call. Jennefer
More informationINTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of microwave endometrial ablation Introduction This overview has been prepared to assist
More informationZurich Open Repository and Archive
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich http://www.zora.uzh.ch Year: 2008 Partial and complete expulsion of the Multiload 375 IUD and the levonorgestrel-releasing
More informationExtended use of intrauterine devices: How long can we go?
Extended use of intrauterine devices: How long can we go? Justine P. Wu, MD, MPH Sarah Pickle, MD Rutgers Robert Wood Johnson Medical School Department of Family Medicine & Community Health Disclosures
More informationPackage leaflet: Information for the user. Levonorgestrel 1.5 mg Tablet. levonorgestrel
Package leaflet: Information for the user Levonorgestrel 1.5 mg Tablet levonorgestrel Read all of this leaflet carefully before you start taking this medicine because it contains important information
More informationAbnormal Uterine Bleeding Case Studies
Case Study 1 Abnormal Uterine Bleeding Case Studies Abigail, a 24 year old female, presents to your office complaining that her menstrual cycles have become a problem. They are now lasting 6 7 days instead
More informationContraception: I. Non-Hormonal Methods
Contraception: I. Non-Hormonal Methods Prof. Karim Hassanein I. Abd- El-Maeboud OB/GYN Department Ain Shams University Family Planning A Branch of Reproductive Health Service (RHS). Def.: In advance regulation
More informationMultipurpose Intravaginal Ring: Tenofovir / Levonorgestrel
MTN Annual Meeting Bethesda, MD March 17, 2015 Multipurpose Intravaginal Ring: Tenofovir / Levonorgestrel Christine Mauck, MD, MPH Why develop a multipurpose ring? Providing drug in a ring is likely to
More informationYunnan Institute of Population and Family Planning Research, Kunming, China 4
517259APH27210.1177/1010539513517259Asia-Pacific Journal of Public HealthZhou et al research-article2014 Article Temporal Trends of Copper-Bearing Intrauterine Device Discontinuation: A Population-Based
More informationTranscervical Sterilization
Q UESTIONS & ANSWERS A BOUT Transcervical Sterilization A New Choice in Permanent Birth Control Choosing a Birth Control Method Women and their partners now have more birth control choices than ever. How
More informationNHS Lothian Patient Group Direction Version: 007. Title: Levonorgestrel 1500mcg for Emergency Contraception
PATIENT GROUP DIRECTION FOR THE ADMINISTRATION OF LEVORGESTREL 1500mcg FOR EMERGENCY CONTRACEPTION BY DESIGNATED HEALTHCARE PROFESSIONALS PROVIDING SEXUAL HEALTH SERVICES, UNSCHEDULED CARE SERVICES OR
More informationContraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital
Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital Disclosures I have no conflicts of interest Contraception: Common Problems How to discuss contraception
More informationContraception and gynecological pathologies
1 Contraception and gynecological pathologies 18 years old, 2 CMI normal First menstruation at 14 years old Irregular (every 2/3 months), painful + She does not need contraception She is worried about
More informationThe number of women using long-acting reversible
Long-acting reversible contraception: Who, what, when, and how This review provides practical tips and dispels some common misconceptions about these devices, which have higher rates of patient satisfaction
More informationStudy design Population Results Strengths Weaknesses Quality
Author Year Tasci, 2008 Chattopdh yay, 2011 Desai, 2012 Study design Population Results Strengths Weaknesses Quality observational Location: Turkey Age range: 32-53 observational Location: India Age range:
More informationDr Mary Birdsall. Fertility Associates Auckland
Dr Mary Birdsall Fertility Associates Auckland Period Problems Mary Birdsall Medical Director Fertility Associates Auckland Period Problems Basic Physiology No Periods Irregular Periods Heavy Periods
More informationUlipristal (ellaone ) for post-coital contraception
for post-coital contraception Author: William Horsley Lead Pharmacist for NETAG September 2009 Summary Ulipristal is a first-in-class progesterone receptor modulator licensed for post coital ( emergency
More informationMIDWIVES IN CONTRACEPTION AND FERTILITY PLANNING 15 TH ANNUAL SOMSA CONGRESS BLOEMFONTEIN AUGUST 2018
MIDWIVES IN CONTRACEPTION AND FERTILITY PLANNING 15 TH ANNUAL SOMSA CONGRESS BLOEMFONTEIN AUGUST 2018 Contraception is every health care workers responsibility # SOMSA Congress: Quality and Respectful
More informationContraceptive. Ready Lessons II. What Can a Contraceptive Security Champion Do?
Contraceptive Lesson Security Ready Lessons II Expand client choice and contraceptive security by supporting access to underutilized family planning methods. What Can a Contraceptive Security Champion
More informationSlid e 1. This slide should be shown at each presentation. This slide should be shown at each presentation. Slid e 2. Slid e 3
e 1 New Developments in Contraception This slide should be shown at each presentation. Counseling and Insertion Training Featuring the Levonorgestrel Intrauterine System Sponsored by Association of Reproductive
More informationOriginal Article ABSTRACT
Original Article Effectiveness and safety of Levonorgestrel Releasing Intrauterine System in treatment of menorrhagia secondary to oral anticoagulations and chronic liver disease Abeera Choudry, Ayesha
More informationF REQUENTLY A SKED Q UESTIONS
Polycystic heart, blood vessels, and appearance. Women with PCOS have these characteristics: Ovarian high levels of male hormones, also called androgens an irregular or no menstrual cycle Syndrome may
More informationCONTRACEPTION OLD FRIENDS, NEW TRENDS
CONTRACEPTION OLD FRIENDS, NEW TRENDS AAP RECOMMENDATIONS 2014 1. Council about and ensure access to all contraceptive methods safe and appropriate describing most effective first. PEDIATRICS 134 (4)
More informationCLEAR COVERAGE HYSTERECTOMY CHECKLISTS
CLEAR COVERAGE HYSTERECTOMY CHECKLISTS Click on the link below to access the checklist sheet. Abnormal Uterine Bleeding Adenomyosis Chronic Abdominal or Pelvic Pain Endometriosis Fibroids General Guidelines
More informationCan you imagine reversible birth control that s more than 99% effective and 100% hormone free, too?
Can you imagine reversible birth control that s more than 99% effective and 100% hormone free, too? BIRTH CONTROL THAT FITS YOUR LIFE, NATURALLY. ParaGard is a registered trademark of Teva Women s Health,
More information16 East 40 th St, 2 nd Fl, New York, NY Ph fax
Page 1 of 9 16 East 40 th St, 2 nd Fl, New York, NY 10016 Ph 212-679-2289 fax 212-679-2288 Please complete the following: Fertility Evaluation Name: Date of birth: Age: Partner s Name: Date of birth: Age:
More informationLinda Gregg NP, Janet Isabell NP, Sue Montei NP Clinical Reviewers Reproductive Health Unit
Linda Gregg NP, Janet Isabell NP, Sue Montei NP Clinical Reviewers Reproductive Health Unit What We Plan To Do Describe the U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 (U.S. MEC) Explain
More informationDr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre
Dr. Nancy Van Eyk Associate Professor, Dalhousie University Chief of Gynaecology, IWK Health Centre AUB Outline Terminology Classification/Etiology Assessment Treatment Referral to Gynaecology U c pt 4
More informationLong Acting Reversible Contraception: First Line Care for Adolescents. David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG
Long Acting Reversible Contraception: First Line Care for Adolescents David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG Disclosures Melissa Kottke is a Nexplanon trainer for Merck Objectives Describe
More informationWendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa
Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa Objectives Distinguish the different types of IUDs Understand the mechanism of action and selection of candidates
More informationVCHIP LARC Needs Assessment Survey
VCHIP LARC Needs Assessment Survey Demographics 1. How many have you been in practice (post-training)? Choose one of the following answers 0-5 6-10 11-15 16-20 21 or more 2. What are your professional
More informationAccording to data from the 2006 to 2008 National Survey
ORIGINAL RESEARCH Modeled Cost Differences Associated With Use of Levonorgestrel Intrauterine Devices Amy Law, PharmD; Mark McCoy, PharmD, MBA; Melissa Lingohr-Smith, PhD; Jay Lin, PhD, MBA; and Richard
More informationJadelle Levonorgestral Rod Implants: Profile and Lessons
Jadelle Levonorgestral Rod Implants: Profile and Lessons John W. Townsend PhD Katherine Williams MHS LA/PM Community of Practice Meeting Washington DC June 23, 2009 Client Needs and Program Challenges
More information